Incyte
NEWS
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
Results from both late-stage trials were announced this week.
MorphoSys AG and Incyte Corporation announced that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys’ proprietary anti-CD19 antibody tafasitamab globally.
MorphoSys AG announces that it has entered into a global collaboration and licensing agreement with Incyte Corporation to further develop and commercialize MorphoSys’ proprietary anti-CD19 antibody tafasitamab.
MorphoSys AG and Incyte Corporation have inked a collaboration and license deal to further develop and commercialize MorphoSys’ anti-CD19 antibody tafasitamab around the world.
Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.
Company shares dropped almost 10% at the news.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
JOBS
IN THE PRESS